Phenolphthalein laxatives human surveillance study proposed by Novartis.
This article was originally published in The Tan Sheet
Executive Summary
PHENOLPHTHALEIN LAXATIVES HUMAN SURVEILLANCE STUDY PROPOSED by Novartis Consumer Health in June 11 comments to FDA. Pointing out that "to date, there have been no human studies that call into question the safety of phenolphthalein," Novartis, the maker of Ex-Lax, suggests conducting a case control human surveillance study to assess whether the use of phenolphthalein-containing laxatives is cause for safety concern. FDA's Carcinogenic Assessment Committee told the agency it believes existing data indicate that the ingredient presents "carcinogenic risk for humans" under conditions of exposure associated with use of phenolphthalein as an OTC laxative ("The Tan Sheet" May 26, p. 12).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning